Natalie Esparza, MD
Urology · Oklahoma City, OKNPI 1710914718
Payments from drug & device makers
Across 297 payments — averaging $18.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$1K
- Pfizer$652
- AbbVie$601
- Medtronic$443
- Johnson & Johnson$319
- Sumitomo Pharma America, Inc.$271
- plus $2K from 31 others
What the payments were for
- Food & beverage$5,33098%
- Education$882%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 82 | $1,252 |
| Pfizer | 33 | $652 |
| AbbVie(2 entities) | 39 | $601 |
| Medtronic | 22 | $443 |
| Johnson & Johnson | 14 | $319 |
| Sumitomo Pharma America, Inc. | 12 | $271 |
| Boston Scientific | 8 | $239 |
| Myriad Genetic Laboratories, Inc. | 16 | $207 |
| Axonics, Inc. | 4 | $170 |
| Blue Earth Diagnostics | 7 | $124 |
| Antares Pharma, Inc. | 5 | $84 |
| Accord Healthcare, Inc. | 5 | $84 |
| Bayer | 4 | $78 |
| Ferring Pharmaceuticals Inc. | 4 | $68 |
| Sun Pharmaceutical Industries Inc. | 3 | $60 |
| Progenics Pharmaceuticals, Inc. | 3 | $59 |
| Myovant Sciences Inc. | 3 | $58 |
| Verity Pharmaceuticals Inc. | 3 | $57 |
| Urovant Sciences Inc | 3 | $56 |
| Merck | 2 | $51 |
| Endo Pharmaceuticals Inc. | 3 | $48 |
| Dendreon Pharmaceuticals LLC | 2 | $42 |
| Travere Therapeutics, Inc. | 2 | $42 |
| Ambu Inc. | 2 | $38 |
| Vertex | 2 | $38 |
| Urogen Pharma, Inc. | 2 | $36 |
| Janssen Scientific Affairs, LLC | 1 | $30 |
| Novartis | 1 | $28 |
| Teleflex LLC | 1 | $27 |
| Tolmar Pharmaceuticals, Inc. | 2 | $27 |
| Endo USA, Inc. | 1 | $23 |
| Civco Medical Instruments | 1 | $20 |
| Trevena, Inc. | 1 | $19 |
| Clarus Therapeutics Inc. | 1 | $18 |
| Cook Medical LLC | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
| Coloplast | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,418 in reported general payments places this provider in the 55th percentile of 145 urology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 228 | $177,822 |
| GemtesaVibegron | 150 | $130,133 |
| Methenamine Hippurate | 169 | $18,104 |
| Solifenacin Succinate | 134 | $8,587 |
| Tolterodine Tartrate ErTolterodine Tartrate | 102 | $8,573 |
| Estradiol | 123 | $8,507 |
| Oxybutynin Chloride ErOxybutynin Chloride | 237 | $4,356 |
| Tamsulosin Hcl | 214 | $4,202 |
| Bethanechol Chloride | 40 | $3,104 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 120 | $2,285 |
| Desmopressin Acetate | 24 | $1,930 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 14 | $1,707 |
| Potassium Citrate ErPotassium Citrate | 15 | $1,562 |
| Doxycycline Hyclate | 122 | $1,533 |
| Finasteride | 70 | $1,159 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $1,252 | $177,822228 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $271 | $130,133150 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 145 urology providers in Oklahoma.
Other urology in Oklahoma City
- Kelly StrattonOklahoma City$1.9M
- Michael CooksonOklahoma City$658K
- Mohammad RamadanOklahoma City$215K
- Basel HassounOklahoma City$46K
- Sanjay PatelOklahoma City$40K
- Ashley BowenOklahoma City$32K
- Sardar Mohammad Khan GalzieOklahoma City$25K
- Dominic FrimbergerOklahoma City$24K
- Johnny HicksonOklahoma City$16K
- Andrew McIntoshOklahoma City$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.